- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07795866
An Exploratory Study to Evaluate Skin Brightening Effects of Different Cosmetic Formulations on UV Irradiated Tanning Model
August 26, 2026 updated by: Unilever R&D
This is a double-blind randomized, complete block design study on Chinese population, expecting approximately 18 participants recruited and at least 10 participants to complete the whole 9-week study.
The study test sites will receive a single 2MED UV radiation .
Study Overview
Status
Not yet recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
13
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sunny Du
- Phone Number: +86 21 22128000
- Email: Sunny.Du@unilever.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy Chinese female or male, aged from 18 to 50 years old (both inclusive).
- Participants in good health condition as per the health history questionnaire with no disease state or physical condition that the investigator believes could interfere with the interpretation of the data.
- Participant is able to read, understand and sign an appropriate informed consent form indicating his willingness to participate.
- ITA° range 10-42°; Skin type III and IV included and can tolerance 2MED radiation.
- No history of allergic diseases or allergies to cosmetics, UV light and other topical preparations.
- No history of photosensitive diseases and no recent use of medications that affect photosensitivity.
- The test area skin (back) should be free of birthmarks, inflammation, scars, excessive hair, etc.
- No cuts, abrasions, fissures, wounds, lacerations on the test site (back).
- Participants must understand the trial process, voluntarily participate in the study, and sign a written informed consent form.
- Willing to attend the study center twice daily for product application during the study period and complete all visits.
Exclusion Criteria:
- Study participants are employees of Sponsor or CRO.
- The study participants participated in test involving the test site within 2 months prior to the start of this test or are currently participating in such tests.
- Study participants had any other visible signs of local irritation, erythema, or skin disease on the visible parts of the body.
- Study participants consider they are prone to breakouts and/or sensitive skin.
- Study participants had a chronic illness or had major surgery in the past year.
- Study participants were receiving any skin treatments on the test sites.
- Study participants had allergies or sensitivities to cleansing products, creams/emulsion, costume jewelry, or other things.
- Female study participants were pregnant/breastfeeding or planning to become pregnant during the trial (study participants self-declared at screening visits).
- Study participants took medication for any condition, which the researchers believe may have affected the interpretation of the data.
- Study participants had a history of psoriasis, eczema, atopic dermatitis, severe acne, etc. Or have other chronic systemic diseases.
- Study participants had received oral or topical corticosteroids and other anti-inflammatory drugs within the last 1 month.
- Study participants used tartaric acid, salicylic acid and any other products or drugs that affect skin colour (such as hydroquinones) within the last 2 months.
- Study participants used retinoic acid preparations or aesthetic treatment such as chemical stripping, laser, pulsed light, etc. in the test site in the past three months.
- Study participants were inevitably exposed to prolonged sunlight.
- Clinical evaluation considers that participants are not suitable for the test.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Untreated
|
|
|
Placebo Comparator: SMR 1
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimental: SMR 2
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimental: SMR 3
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimental: SMR 4
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimental: SMR 5
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Placebo Comparator: Pro-Derma 1
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimental: Pro-Derma 2
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimental: Pro-Derma 3
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimental: Pro-Derma 4
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Experimental: Pro-Derma 5
|
Cosmetic skin brightening product to be applied to defined test site
|
|
Active Comparator: Thiamidol
|
Cosmetic skin brightening product to be applied to defined test site
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
L*, a*, b*, ITA
Time Frame: From 1-week pre-treatment phase to end of study at 8 weeks
|
Measure skin color (L*, a*, b* values, calculate ITA°) on the back test areas using Spectrophotometer, CM-26d.
|
From 1-week pre-treatment phase to end of study at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hydration and barrier function
Time Frame: From 1-week pre-treatment phase to end of study at 8 weeks
|
Measure skin hydration on the back test areas using Corneometer, CM825.
Measure TEWL on the back test areas using Vapometer .
|
From 1-week pre-treatment phase to end of study at 8 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Image demo
Time Frame: From 1-week pre-treatment phase to end of study at 8 weeks
|
Capture images on the back test areas using Antera 3D device.
Capture images on the back test areas using digital camera.
|
From 1-week pre-treatment phase to end of study at 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 10, 2026
Primary Completion (Estimated)
November 11, 2026
Study Completion (Estimated)
November 11, 2026
Study Registration Dates
First Submitted
August 26, 2026
First Submitted That Met QC Criteria
August 26, 2026
First Posted (Actual)
August 31, 2026
Study Record Updates
Last Update Posted (Actual)
August 31, 2026
Last Update Submitted That Met QC Criteria
August 26, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.